Hostname: page-component-cb9f654ff-p5m67 Total loading time: 0 Render date: 2025-08-21T02:30:48.329Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of Intravenous and Subcutaneous Administration of Apomorphine on the Clinical Symptoms of Chronic Schizophrenics

Published online by Cambridge University Press:  29 January 2018

E. K. G. Syvälahti ,
E. Säkö ,
M. Scheinin ,
K. Pihlajamäki  and
J. Hietala
E. K. G. Syvälahti*
Affiliation:
Departments of Pharmacology, Psychiatry and Neurology, University of Turku, Turku 52, Finland
E. Säkö
Affiliation:
Departments of Pharmacology, Psychiatry and Neurology, University of Turku, Turku 52, Finland
M. Scheinin
Affiliation:
Departments of Pharmacology, Psychiatry and Neurology, University of Turku, Turku 52, Finland
K. Pihlajamäki
Affiliation:
Departments of Pharmacology, Psychiatry and Neurology, University of Turku, Turku 52, Finland
J. Hietala
Affiliation:
Departments of Pharmacology, Psychiatry and Neurology, University of Turku, Turku 52, Finland
*
∗ Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

The effects of apomorphine, a stimulant of dopamine autoreceptors, were studied in 12 chronic schizophrenics on neuroleptic treatment; both subcutaneous and intravenous administration were used. Apomorphine has been reported to have therapeutic effects in previous studies but, we were not able to confirm any significant and specific differences in psychotic symptoms or tardive dyskinesia scores with apomorphine administration, compared with placebo. These results do not support the importance of dopamine autoreceptors in the regulation of schizophrenic and dyskinetic symptoms in chronic neuroleptic-treated patients.

Information

Type
Papers
Information
The British Journal of Psychiatry , Volume 148 , Issue 2 , February 1986 , pp. 204 - 208
Copyright
Copyright © 1986 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Bannon, M. J., Reinhard, J. F., Bunney, E. B. & Roth, R. H. (1982) Unique response to antipsychotic drugs is due to absence of terminal auto-receptors in mesocortical dopamine neurones. Nature, 296, 444–446.Google Scholar
Beaumont, P., Bruwer, J., Pimstone, P., Vinie, A. & Utian, W. (1975) Bromoergocryptine in the treatment of phenotiazine-induced galactorrhea. British Journal of Psychiatry, 126, 285–288.Google Scholar
Carlsson, A. (1975) Receptor-mediated control of dopamine metabolism. In: Pre- and Postsynaptic Receptors (ed Usidin, E. & Bunney, W. E.), pp. 49–62. New York: Marcel Dekker.Google Scholar
Carroll, B. J., Curtis, G. C. & Kokmen, E. (1977) Paradoxical response to dopamine, agonists in tardive dyskinesis. American Journal of Psychiatry, 134, 785–789.Google Scholar
Corsini, G. V., Del Zompo, M., Manconi, S., Piccardi, M. P., Onali, P. L. & Mangoni, A. (1977) Evidence for dopamine receptors in the human brain mediating sedation and sleep. Life Sciences, 20, 1613–1618.Google Scholar
Cutler, N. R., Jeste, D. Y., Karowin, F. & Wyatt, R. J. (1982) Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients. Life Sciences, 30, 753–756.Google Scholar
Di Chiara, G., Corsini, G. V., Meren, G. P., Tissari, A. & Gessa, G. L. (1978) Self-inhibitory dopamine receptors: their role in the biochemical and behavioral effects of low doses of apomorphine. Advances in Biochemical Psychopharmacology, 19, 275–292.Google ScholarPubMed
Feldman, F., Susselman, S. K. & Barrera, S. A. (1975) A note on apomorphine as a sedative. American Journal of Psychiatry, 62, 403–405.Google Scholar
Ferrier, I. N., Johnstone, E. C. & Crow, J. (1984) Clinical effects of apomorphine in schizophrenia. British Journal of Psychiatry, 144, 341–348.Google Scholar
Gerlach, J. (1979) Tardive dyskinesia. Doctoral thesis, Copenhagen: Laegeforeningens forlag.Google Scholar
Guy, W. (1976) ECDEV Assessment Manual for Psychopathology. Washington DC: Department of Health, Education and Welfare.Google Scholar
Hollister, L. E. (1981) Experiences with dopamine agonists in depression and schizophrenia. In: Apomorphine and Other Dopamimetrics (eds Corsini, G. V. and Gessa, G. L.), New York: Raven Press.Google Scholar
Jeste, D. V., Zalcman, S., Weinberger, D. R., Cutler, N. P., Bigelow, L. B., Kleinman, J. E., Rogol, A. & Wyatt, J. (1983) Apomorphine response and subtyping of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 7, 83–88.Google Scholar
Klawans, H. J., Goetz, C. & Perliz, A. (1980) Tardive dyskinesia: a review and update. American Journal of Psychiatry, 137, 900–908.Google Scholar
Meltzer, H. Y. (1979) Clinical evidence for multiple dopamine receptors in man. Communications in Psychopharmacology, 3, 457–470.Google Scholar
Meltzer, H. Y. (1980) Relevance of dopamine autoreceptors for psychiatry. Schizophrenia Bulletin, 2, 456–475.CrossRefGoogle Scholar
Meltzer, H. Y. (1982) Dopamine autoreceptor stimulation: clinical significance. Pharmacology Biochemistry & Behaviour, 17 (Suppl 1), 1–10.Google Scholar
Meltzer, H. Y., Kolakowska, T., Robertson, A. & Tricon, B. J. (1983) Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy. Psychopharmacology, 81, 37–41.CrossRefGoogle ScholarPubMed
Nowycky, M. C. & Roth, R. H. (1977) Presynaptic dopamine receptors. Development of supersensitivity following treatment with fluphenazine decanoate. Naunyn—Schmiedeberg's Archives and Pharmacology, 300, 247–254.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) Brief Psychiatric Rating Scale (BPRS). Psychological Reports. 10, 199–212.Google Scholar
Smith, R. C., Tamminga, C. & Davis, J. M. (1971) Effects of apomorphine of schizophrenic symptoms. Journal of Neural Transmission, 40, 171–176.Google Scholar
Smith, R. C., Tamminga, C. A., Haraszti, J., Pandey, G. N. & Davis, J. M. (1977) Effects of dopamine agonists in tardive dyskinesia. American Journal of Psychiatry, 134, 763–768.Google Scholar
Tamminga, C. A., Schaffer, M. H., Smith, R. C. & Davis, J. M. (1978) Schizophrenic symptoms improve with apomorphine. Science, 200, 567–568.CrossRefGoogle ScholarPubMed
Tamminga, C. A. & Schaffer, M. H. (1979) Treatment of schizophrenia with ergot alkaloids. Psychopharmacology, 66, 239–242.Google Scholar
Tarsy, D., Gardos, G. & Cole, J. O. (1979) The effect of dopamine agonist in tardive dyskinesia. Neorology, 29, 606.Google Scholar
Tolosa, E. S. (1978) Modification of tardive dyskinesia and spasmodic torticollis by apomorphine. Archives of Neurology, 35, 459–462.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.